Fagron N.V.

Transaction in Own Shares • May 20, 2013

DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)¹ , 17 May 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 9 May 2013 to 17 May 2013, it acquired 72,578 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
9 May 2013	5,106	€ 21.2330	€ 20.85	€ 21.44	€ 108,416
10 May 2013	6,279	€ 21.2412	€ 21.10	€ 21.47	€ 133,373
13 May 2013	13,000	€ 21.1787	€ 20.80	€ 21.40	€ 275,323
14 May 2013	48,193	€ 21.7723	€ 21.34	€ 22.00	€ 1,049,272

In addition, during the period from 9 May 2013 to 17 May 2013, Arseus acquired 114,347 treasury shares via various block trades.

Acquisition date	Block	Price	Amount
10 May 2013	1,067	€ 21.15	€ 22,567
10 May 2013	1,473	€ 21.23	€ 31,272
13 May 2013	2,000	€ 20.94	€ 41,880
13 May 2013	5,000	€ 20.86	€ 104,300
13 May 2013	15,000	€ 21.35	€ 320,250
13 May 2013	13,000	€ 21.39	€ 278,070
14 May 2013	2,000	€ 21.50	€ 43,000
14 May 2013	10,000	€ 21.95	€ 219,500
14 May 2013	21,095	€ 21.95	€ 463,035

¹ This press release was sent out by Arseus NV and Arseus BV.

14 May 2013	8,000	€ 21.94	€ 175,520
14 May 2013	7,372	€ 21.90	€ 161,447
14 May 2013	3,617	€ 21.94	€ 79,357
14 May 2013	20,000	€ 21.69	€ 433,800
14 May 2013	1,850	€ 21.91	€ 40,534
14 May 2013	2,873	€ 21.48	€ 61,712

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus held 59,646 treasury shares. As a result of the acquisition of 186,925 treasury shares and the exercise of stock options by members of the Board of Directors, members of the Executive Committee and employees of Arseus, Arseus now holds 1,117 treasury shares.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

Constantijn van Rietschoten Director of Corporate Communications +31 88 33 11 222 (Office) +31 6 53 69 15 85 (Mobile) constantijn.van.rietschoten@arseus.com

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

2/2